24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Ichilov Medical Center
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:43
Full list of Israeli high-tech layoffs in 2025
13:38
Hydrogen startup Electriq Global collapses under nearly $30M in debt, despite raising $25M
11:26
PwC integrates altshare’s algorithm to streamline startup valuations
14:27
Nice beats Q4 estimates but shares plunge on weak 2025 outlook
More stories
Buzz
Most popular
Daily
Weekly
1
Insight Partners hit by cyber attack with possible data leaks
2
CyberArk’s surge, Wiz and Cato prepare for IPOs: Israeli cyber firms ready for the next big move
3
How Intel ruined an Israeli startup it bought for $2B—and lost the AI race
4
Riskified cuts staff as struggles continue
5
Techtonic to invest over $140 million to build one of Israel's largest data centers
More news
Ichilov Medical Center
2 stories about Ichilov Medical Center
"The genome project will change the face of medicine in Israel and save human lives"
10.11.24
|
Roni Dori
Psifas is an ambitious new genome project aiming to create a genetic database of Israel’s citizens, with a budget of NIS 250 million. The collected information already provides information that will make it possible to treat life-threatening diseases in the subjects. The hope is that after accumulating 100,000 samples, the database will help jumpstart the biotech industry. CEO Prof. Gabi Barbash: "Psifas is a great achievement and advantage for Israel, which aspires to become a global hub of biotechnological information."
BioLight to partner with Ichilov Medical Center to develop innovative ophthalmology technologies
29.11.21
|
CTech
According to the terms of the agreement, the company will retain the primary right to license technologies developed at Ichilov